174 related articles for article (PubMed ID: 38708158)
1. A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy.
Boppana M; Sengar M; Jain H; Gurjar M; Ambotkar M; Gota V; Bonda A; Bagal B; Thorat J; Gokarn A; Nayak L; Shetty N; Baheti A; Mokal S; Kannan S; Shetty A; Eipe T
Indian J Hematol Blood Transfus; 2024 Apr; 40(2):204-212. PubMed ID: 38708158
[TBL] [Abstract][Full Text] [Related]
2. Exposure-Response Relationship of Posaconazole Suspension in Theprophylaxis of Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Sengar M; Jain H; D'souza S; Kannan S; Mokal S; Gurjar M; Ambotkar M; Sharma N; Boppanna M; Gota V
Indian J Hematol Blood Transfus; 2023 Apr; 39(2):200-207. PubMed ID: 37006974
[TBL] [Abstract][Full Text] [Related]
3. Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.
Cattaneo C; Panzali A; Passi A; Borlenghi E; Lamorgese C; Petullà M; Re A; Caimi L; Rossi G
Mycoses; 2015 Jun; 58(6):362-7. PubMed ID: 25907298
[TBL] [Abstract][Full Text] [Related]
4. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
5. Real-life comparison of posaconazole versus fluconazole for primary antifungal prophylaxis during remission-induction chemotherapy for acute leukemia.
Dufresne SF; Bergeron J; Beauchemin S; Abou Chakra CN; Vadnais B; Bouchard P; Labbé AC; Laverdière M
J Assoc Med Microbiol Infect Dis Can; 2023 Mar; 8(1):18-28. PubMed ID: 37008582
[TBL] [Abstract][Full Text] [Related]
6. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
[TBL] [Abstract][Full Text] [Related]
7. Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy.
Mishra P; Agrawal N; Bhurani D; Agarwal NB
Indian J Hematol Blood Transfus; 2020 Jan; 36(1):64-70. PubMed ID: 32174692
[TBL] [Abstract][Full Text] [Related]
8. [Primary antifungal prophylaxis with posaconazole plays a pivotal role during chemotherapy of acute myeloid leukemia].
Gong BF; Liu YT; Zhang GJ; Wei SN; Li Y; Liu KQ; Gong XY; Zhao XL; Qiu SW; Gu RX; Lin D; Wei H; Zhou CL; Liu BC; Wang Y; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):528-531. PubMed ID: 28655098
[No Abstract] [Full Text] [Related]
9. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
10. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
[TBL] [Abstract][Full Text] [Related]
11. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
[TBL] [Abstract][Full Text] [Related]
12. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.
Mattiuzzi G; Yilmaz M; Kantarjian H; Borthakur G; Konopleva M; Jabbour E; Brown Y; Pierce S; Cortes J
J Infect Chemother; 2015 Sep; 21(9):663-7. PubMed ID: 26141814
[TBL] [Abstract][Full Text] [Related]
14. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
[TBL] [Abstract][Full Text] [Related]
17. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
19. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
20. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]